Zhu Xiaonian, Zhang Shidong, Tan Shengkui, Li Di, Chen Xiaoyi, Kong Juan, Fu Yuanyuan, Wang Changming, Wen Li
Department of Respiratory, the Affiliated Guilin People's Hospital of Guilin Medical University, Guilin, China.
Department of Epidemiology and Health Statistics, School of Public Health, Guilin Medical University, Guilin, China.
Transl Cancer Res. 2020 Oct;9(10):6214-6220. doi: 10.21037/tcr-20-1254.
Human chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is implicated in the pathogenesis of immune, reproductive systems and various cancers. However, the expression and clinical significance of CMTM4 in lung cancer have not been identified.
We performed immunohistochemistry to detect the expression of CMTM4 in 75 paired lung adenocarcinoma and non-tumor lung tissues. The correlation between CMTM4 expression and clinical significance of lung cancer patients was analyzed by Chi-square test. Kaplan-Meier method and Log-Rank test were used to calculate the survival time of lung cancer patients.
We found that CMTM4 was positively expressed in 34/75 (45.3%) cases of lung adenocarcinoma tissues, while positively expressed in 59/75 (78.6%) cases of non-tumor lung tissues, suggesting a lower expression of CMTM4 in lung adenocarcinoma tissues than non-tumor lung tissues (P<0.05). In addition, the negative expression of CMTM4 was associated with gender, smoking, and metastasis in lung cancer patients. Moreover, lung cancer patients with negative expression of CMTM4 had a shorter survival time than the patients with positive expression of CMTM4. COX regression analysis showed that CMTM4 was an independent prognostic factor for the overall survival of lung cancer patients.
Our study supports that CMTM4 can be used as a new marker for the treatment and prognosis of lung cancer.
人趋化因子样因子（CKLF）样含MARVEL跨膜结构域家族（CMTM）与免疫、生殖系统及多种癌症的发病机制有关。然而，CMTM4在肺癌中的表达及临床意义尚未明确。
我们采用免疫组织化学方法检测75对肺腺癌组织和癌旁非肿瘤肺组织中CMTM4的表达。采用卡方检验分析CMTM4表达与肺癌患者临床意义之间的相关性。采用Kaplan-Meier法和Log-Rank检验计算肺癌患者的生存时间。
我们发现CMTM4在34/75（45.3%）例肺腺癌组织中呈阳性表达，而在59/75（78.6%）例非肿瘤肺组织中呈阳性表达，提示CMTM4在肺腺癌组织中的表达低于非肿瘤肺组织（P<0.05）。此外，CMTM4的阴性表达与肺癌患者的性别、吸烟及转移有关。而且，CMTM4表达阴性的肺癌患者生存时间短于CMTM4表达阳性的患者。COX回归分析显示，CMTM4是肺癌患者总生存的独立预后因素。
我们的研究支持CMTM4可作为肺癌治疗和预后的新标志物。
